Porton Fine Chemicals Ltd - Asset Resilience Ratio
Porton Fine Chemicals Ltd (300363) has an Asset Resilience Ratio of 6.85% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore Porton Fine Chemicals Ltd (300363) long-term investment share to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2020)
This chart shows how Porton Fine Chemicals Ltd's Asset Resilience Ratio has changed over time. See 300363 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Porton Fine Chemicals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Porton Fine Chemicals Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥588.05 Million | 6.85% |
| Total Liquid Assets | CN¥588.05 Million | 6.85% |
Asset Resilience Insights
- Limited Liquidity: Porton Fine Chemicals Ltd maintains only 6.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Porton Fine Chemicals Ltd Industry Peers by Asset Resilience Ratio
Compare Porton Fine Chemicals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Krka d. d
WAR:KRK |
Drug Manufacturers - Specialty & Generic | 11.18% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263 |
Drug Manufacturers - Specialty & Generic | 6.08% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Porton Fine Chemicals Ltd (2017–2020)
The table below shows the annual Asset Resilience Ratio data for Porton Fine Chemicals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.09% | CN¥4.14 Million ≈ $605.43K |
CN¥4.50 Billion ≈ $658.04 Million |
+0.09pp |
| 2019-12-31 | 0.01% | CN¥224.20K ≈ $32.81K |
CN¥3.96 Billion ≈ $578.81 Million |
-13.03pp |
| 2018-12-31 | 13.03% | CN¥570.21 Million ≈ $83.44 Million |
CN¥4.37 Billion ≈ $640.12 Million |
+13.00pp |
| 2017-12-31 | 0.04% | CN¥1.06 Million ≈ $155.70K |
CN¥2.85 Billion ≈ $416.76 Million |
-- |
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more